Literature DB >> 18086415

Viral drug resistance and fitness.

Miguel E Quiñones-Mateu1, Dawn M Moore-Dudley, Oyebisi Jegede, Jan Weber, Eric J Arts.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18086415     DOI： 10.1016/S1054-3589(07)56009-6

Source DB:  PubMed          Journal:  Adv Pharmacol        ISSN： 1054-3589


× No keyword cloud information.
  16 in total

1.  Uncommon pathways of immune escape attenuate HIV-1 integrase replication capacity.

Authors:  Mark A Brockman; Denis R Chopera; Alex Olvera; Chanson J Brumme; Jennifer Sela; Tristan J Markle; Eric Martin; Jonathan M Carlson; Anh Q Le; Rachel McGovern; Peter K Cheung; Anthony D Kelleher; Heiko Jessen; Martin Markowitz; Eric Rosenberg; Nicole Frahm; Jorge Sanchez; Simon Mallal; Mina John; P Richard Harrigan; David Heckerman; Christian Brander; Bruce D Walker; Zabrina L Brumme
Journal:  J Virol       Date:  2012-04-11       Impact factor: 5.103

Review 2.  Mixing the right hepatitis C inhibitor cocktail.

Authors:  Michael A Gelman; Jeffrey S Glenn
Journal:  Trends Mol Med       Date:  2010-11-23       Impact factor: 11.951

3.  Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.

Authors:  Philippe Selhorst; Ana C Vazquez; Katty Terrazas-Aranda; Johan Michiels; Katleen Vereecken; Leo Heyndrickx; Jan Weber; Miguel E Quiñones-Mateu; Kevin K Ariën; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

Review 4.  HIV-1 antiretroviral drug therapy.

Authors:  Eric J Arts; Daria J Hazuda
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

5.  In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy.

Authors:  Tanya Lynn Applegate; Donald John Birkett; Glen John Mcintyre; Angel Belisario Jaramillo; Geoff Symonds; John Michael Murray
Journal:  Retrovirology       Date:  2010-10-09       Impact factor: 4.602

6.  Distinct effects of two HIV-1 capsid assembly inhibitor families that bind the same site within the N-terminal domain of the viral CA protein.

Authors:  Christopher T Lemke; Steve Titolo; Uta von Schwedler; Nathalie Goudreau; Jean-François Mercier; Elizabeth Wardrop; Anne-Marie Faucher; René Coulombe; Soma S R Banik; Lee Fader; Alexandre Gagnon; Stephen H Kawai; Jean Rancourt; Martin Tremblay; Christiane Yoakim; Bruno Simoneau; Jacques Archambault; Wesley I Sundquist; Stephen W Mason
Journal:  J Virol       Date:  2012-04-11       Impact factor: 5.103

7.  NMR and MD studies combined to elucidate inhibitor and water interactions of HIV-1 protease and their modulations with resistance mutations.

Authors:  Rieko Ishima; Nese Kurt Yilmaz; Celia A Schiffer
Journal:  J Biomol NMR       Date:  2019-06-26       Impact factor: 2.835

8.  Probing Structural Changes among Analogous Inhibitor-Bound Forms of HIV-1 Protease and a Drug-Resistant Mutant in Solution by Nuclear Magnetic Resonance.

Authors:  Shahid N Khan; John D Persons; Janet L Paulsen; Michel Guerrero; Celia A Schiffer; Nese Kurt-Yilmaz; Rieko Ishima
Journal:  Biochemistry       Date:  2018-02-19       Impact factor: 3.162

9.  The impact of individual human immunodeficiency virus type 1 protease mutations on drug susceptibility is highly influenced by complex interactions with the background protease sequence.

Authors:  H Van Marck; I Dierynck; G Kraus; S Hallenberger; T Pattery; G Muyldermans; L Geeraert; L Borozdina; R Bonesteel; C Aston; E Shaw; Q Chen; C Martinez; V Koka; J Lee; E Chi; M-P de Béthune; K Hertogs
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

10.  Predictive value of HIV-1 genotypic resistance test interpretation algorithms.

Authors:  Soo-Yon Rhee; W Jeffrey Fessel; Tommy F Liu; Natalia M Marlowe; Charles M Rowland; Richard A Rode; Anne-Mieke Vandamme; Kristel Van Laethem; Françoise Brun-Vezinet; Vincent Calvez; Jonathan Taylor; Leo Hurley; Michael Horberg; Robert W Shafer
Journal:  J Infect Dis       Date:  2009-08-01       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.